How will biopharma evolve, where should we look for innovation, and how can we address challenges in ensuring patient access to modern therapies? Answers to these questions and more can be found in the latest edition of Euro Health Leaders, featuring an interview with Jeremy Launders.
In his conversation with Euro Health Leaders, the CEO emphasized that BIOTON not only ensures a stable supply of insulin but also actively develops new therapeutic solutions that could transform the future of diabetology. These efforts are crucial in light of the increasing demand for insulin and global health challenges.
Jeremy Launders also highlighted the importance of investing in technologies that can revolutionize diabetes treatment. Currently, BIOTON is working on:
- Modern insulin delivery methods, including an innovative transdermal drug delivery technology
- An AI-powered application for monitoring patients’ health parameters
- The introduction of five new oral diabetes therapies by 2028
Each of these innovations directly responds to global projections of rising diabetes cases in the coming years.
One of the key topics of the interview was Launders’ approach to organizational management. At BIOTON, the fundamental principle is to foster a culture of collaboration, trust, and innovation.
The CEO emphasized that his business decisions are always guided by three core values:
- Integrity – making decisions in accordance with the highest ethical standards
- Transparency – open communication and building trust among employees and partners
- Putting Patients First – every BIOTON product is developed with patient safety and well-being in mind
Launders stated that his decision-making philosophy is based on a simple question:
Would I give this medication to a loved one?
Thanks to this approach, every innovation and product at BIOTON meets the highest quality and safety standards.
As a responsible pharmaceutical company, BIOTON actively undertakes initiatives to support sustainable development and minimize environmental impact. In the interview, Launders also highlighted BIOTON’s commitment to its ESG strategy, ensuring that the company operates in an environmentally responsible manner.
Recent sustainability investments include:
- A 1.9 MW photovoltaic farm, covering 15% of the company’s energy needs
- Advanced energy-saving technologies and CO₂ emission reduction initiatives
- Resource management systems that reduce waste and improve production efficiency
The full article is available in Euro Health Leaders: